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INTRODUCTION 
 With the continuing advancements in our understanding of the human genome, new 
techniques and methods are being employed to alter genetic expression. The study of the 
modification of gene expression without changing the gene is known as epigenetics10. Epigenetic 
changes include DNA methylation and histone modification, both of which regulate chromatin 
remodeling to ensure gene expression regulation and stable gene silencing7. Since epigenetic 
alterations occur during early stages of carcinogenesis and have been identified as possible 
initiators of cancer development, epigenetic alterations have become a great interest in both the 
realms of nutritional sciences and cancer, as nutrition plays a role in the ability to modify gene 
expression as well as protect the genome from damage3,8.  
Cell cycle regulation, DNA damage repair potential, induction of apoptosis, 
inflammatory response signaling, and cell growth differentiation and control are some of the 
many important deregulated cellular functions and pathways during carcinogenesis. Epigenetic 
alterations, including promoter hypermethylation and global hypomethylation can lead to tumor 
suppressor gene silencing and chromosomal instability, respectively, contributing to 
carcinogenesis3. It is hypothesized that either histone modifications affect chromosome function 
through the alteration of histone electrostatic charge, resulting in altered histone structure or 
DNA binding; or that modifications act as binding sites for protein recognition motifs1,10.  
Several dietary components including folate, polyphenols, selenium, retinoids, isothiocyanates, 
and fatty acids have shown anti-carcinogenic epigenetic potential by disrupting many of the 
deregulated processes such as tumor suppressor gene promoter hypermethylation, histone onco-
modifications, as well as global DNA hypomethylation9.  
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Statement of the Controversy 
Despite the potential for nutriepigenetics to be used as targets in cancer prevention and 
management, the full capabilities of this type of treatment still remains relatively undiscovered. 
Currently, much of the research is derived from in vitro and in vivo studies, with in vivo animal 
studies being favored due to the ability to control and select for minimal genetic variations and 
modulate dietary intake, whereas human cancer cases are difficult to control for diet and a 
patient’s specific genotype that might be contributing to cancer risk3,8. This challenge highlights 
“the need for highly controlled genotypes and environmental conditions that allow for 
identifying different regulatory patterns based on diet and genotype” according to the Journal of 
Environmental Health Perspectives8. Utilizing nutriepigenetics as a viable treatment for cancer 
risk and prevention remains contested, as outcome is largely based on a case-by-case basis, and 
is highly dependent on the specific gene, target organ, cell type, as well as dosing and timing of 
specific nutrients6,9.  
Bioactive food components, nonessential molecules present in foods that exhibit the 
capacity to moderate metabolic processes, have been shown to modulate DNA and histone 
methylation, as well as cancer susceptibility14. Dietary components such as folate are involved in 
one-carbon metabolism and are vital in DNA methylation due to their influence on the resupply 
of methyl groups in methylation metabolic pathways6,14. Folate, in the form of 5’-methylTHF, is 
involved in the remethylation of homocysteine to methionine, a precursor to the primary methyl 
group donor for most methylation reactions, S-adenosylmehtionine(SAM)6,14.   
 The purpose of this thesis paper is to examine the current state of nutriepigenetics in cancer 
risk reduction and prevention. The paper will review the role the bioactive food component folate 
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has in DNA methylation and histone modification, and will explore the strengths as well as 
limitations of the current research.  
LITERATURE REVIEW 
 DNA methylation is a key epigenetic component that modifies DNA directly and regulates 
gene integrity and expression through the methylation of CpG dinucleotide residue cytosine bases 
at the 5’ carbon end5,7. Within certain genes, CpG dinucleotides are also sites for mutation in 
human cancers, accounting for up to 30% of all germline point mutations6. With age comes the 
occurrence of genomic DNA hypomethylation, gene and tissue specific promoter DNA 
hypermethylation, as well as declined folate status, and leaves telomere sequences prone to DNA 
strand breaks, potentially shortening telomere length. This shortening is associated with reduced 
life span, and is a proposed mechanism of age-related diseases such as cancer5. This link between 
age and cancer is purported due to hypomethylation and hypermethylation occurring in both states. 
Decreased DNA methylation is believed to promote chromosomal instability, loss of imprinting in 
transcription, as well as up-regulation of silent genes which is thought to lead to carcinogenesis 
and tumor development.  
Even in utero, DNA methylation patterns established by maternal diet play a role in 
protection of pediatric disease development and later life health, as shown by maternal mice methyl 
group diet supplementation permanently altering offspring phenotype through elevated 
methylation at the promoter CpG site6. Folate aids in the regeneration of DNA methylation methyl 
groups through one carbon metabolism, with early exposure being hypothesized to prevent tumors 
through its provision of methyl groups in sustaining normal methylation patterns and DNA repair2. 
Low folate status however decreases levels of the methyl donor S-adenosylmethionine (SAM), 
while also increasing levels of methyl-transferase inhibitor S-adenosylhomocysteine (SAH)2,5,6,9. 
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An in vitro study of untransformed mammalian cell lines, a mouse fibroblast and hamster ovary, 
as well as human colon adenocarcinoma cell lines (HCT116/Caco-2) explored the effect of folate 
on SAM and SAH concentrations. Folate alone was adequate to reduce SAM pools, leading to an 
increase in SAH levels, which is believed to lead to reduced methyltransferase activity. It was 
found however that SAM: SAH ratios were actually significantly higher in the folate depleted 
mouse fibroblast and HCT human cell lines16. Furthermore, only the untransformed cell lines 
showed significant change in genomic DNA methylation in folate deficient cells, with a 28% 
reduction in DNMT activity in the fibroblast cells but no significant change in the ovary cell line. 
These results support that folate deficiency results are dependent on cell type, and that genomic 
DNA methylation may be independent of SAM:SAH ratios. 
Epidemiologic studies have shown an inverse relation between folate status and the risk of 
cancers such as lung, esophageal, stomach, colorectal, pancreatic, breast, as well as 
neuroblastomas and leukemia6. Of these cancers, colorectal cancer management has shown 
promise, as results from the epidemiologic studies report a 20-40% risk reduction in participants 
with high dietary intake of folate compared to those with low folate status. A number of small 
intervention studies have illustrated the improvement and reversal of surrogate endpoint 
biomarkers of colorectal cancer with folate supplementation6. Data from animal studies also 
support a negative correlation between folate status and colorectal cancer risk, as folate 
supplementation was linked with restored methylation status in colon cancer cells6,9. Despite this 
correlation, moderate and sustained folate deficiency alone did not induce significant DNA 
hypomethylation in DMH, a carcinogen to promote rat colon carcinogenesis. It was however 
observed that a significant hypomethylation of p53 tumor suppressor gene occurred at some exons 
in the DMH rat colon, suggesting that effect of folate status on DNA methylation patterns may be 
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site and gene-specific5,6. Inconsistent changes in p53 methylation in rat colon due to folate status 
also suggests that methylation changes in the are dependent on total methyl donor supply rather 
than folate alone6.  
Further research on the effects of folate status on DNA methylation in in vitro systems 
support the assertion that DNA methylation changes are site and gene specific, as well as the 
direction of these changes being potentially dependent on cell and target organ specific. Human 
clinical trials have shown reduced DNA methylation in leukocytes in response to folate depletion 
that was restored after subsequent folate supplementation, while several other studies have 
observed no significant correlation between lymphocyte DNA methylation and folate and 
homocysteine concentrations. At least two studies identified a positive correlation between colonic 
DNA methylation and folate concentrations as well as a negative correlation with homocysteine 
levels in individuals with and without colon adenomas and adneocarcinomas6. Further human 
intervention studies focusing on folate supplementation remains divided, as sustained 
supplementation of folate 12.5-25 times the daily requirement significantly increased colonic DNA 
methylation in individuals with resected colorectal adenoma, while showing no significant effect 
on patients with chronic ulcerative colitis who received the same dosing6. These human studies 
further support the hypothesis of the correlation between folate status and genomic DNA 
methylation being dependent on site and tissue, as well as the level of folate supplementation and 
depletion. It still remains inconclusive on the extent of folate deficiency and the statistical 
significance in DNA methylation reduction, both on a genomic and site/gene specific level2,6.  
Fragile histidine triad (FHIT), is a tumor suppressor gene that is commonly silenced in 
cervical cancer. Promoter hypermethylation has been observed in this cancer, leading to FHIT 
silencing. In order to evaluate the influence of folate in FHIT expression, a cross-sectional study 
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was conducted on 250 women, including those with normal cervix cells, neoplasm grade 1/2, as 
well as squamous cell carcinoma15. Two different cell lines were treated with increasing levels of 
folate, ranging from 0 to 1000 micrograms. It was found that folate status was significantly reduced 
the more severe the cervical cancer was. Furthermore, FHIT promoter methylation was 
significantly higher in all cervical cancer groups. It was shown that apoptosis rate and proliferation 
inhibition rate was positively correlated with folate concentration, while no significant differences 
were seen between the two cell lines. Western blotting also showed that promoter methylation 
weakened with higher folate concentrations. Protein expression of FHIT was significantly higher 
between 0 and 100 micrograms of folate supplementation, while no significant change was seen 
between 100 micrograms and higher folate concentrations. This cross-sectional study supports 
folate’s role in modulating cervical cancer risk, as folate was found to be a significant factor in 
FHIT gene hypermethylation15.  
Prostate cells have also been shown to be sensitive to folate, as seen through an in vivo 
study on 100 microgram folate depletion in 3 mouse prostate cancer cell lines, benign, tumorigenic, 
and metastatic. An analysis of SAM and SAH pools showed a significant decrease in SAM:SAH 
ratios in the benign and tumorigenic but not the metastatic cell line. The benign and tumorigenic 
cell lines also showed reduced intensity of the CpG island, suggesting promoter hypermethylation 
in 100 micrograms of folate deficiency. These epigenetic changes were correlated with increased 
anchorage dependent growth in prostate cells13.  
A cohort study of 1101 members of the Lovelace Smokers cohort conducted a food 
questionnaire and sputum sample, identifying 8 genes commonly methylated and subsequently 
silenced in lung cancer risk and progression. It was found that individuals with high folate and 
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multi-vitamin (with folate present) intake showed significant reduction in promoter methylation 
status, suggesting folate acts as a significant protector against gene methylation in lung cancer17.  
DNA damage, while a relatively common occurrence in cells, still holds the potential to 
lead to genetic mutations and cancer. Histone proteins are crucial components of eukaryotic 
chromatin, acting as spools around which DNA winds, with post translational modifications on 
their tails theorized to be vital in the DNA repair and damage response1. The four core histones, 
H2A, H2B, H3, and H4 form the nucleosome core, and feature DNA-binding motifs that recognize 
specific sequences of DNA1,11. DNA interaction with histone is mediated by the charges of the 
DNA backbone and charged arginine and lysine residues of histones, with modifications to the 
histone altering the histone residue charges, thus controlling chromatin compaction1,10. 
Modifications also serve as high affinity binding sites for protein specific binding domains, and it 
is these modifications to the histone that are involved in tumorigenesis and cancer progression. In 
most lung tumors, the histone demethylase KDM2A is overexpressed, and contributes to tumor 
formation and metastasis11. Histone methylation is a common modification linked to the DNA 
damage response, and it is histone methyltransferases and demethylases, in conjunction with their 
targeted methylation that is responsible for this response1. Histone methylation occurs at specific 
sites, including H3K9 methylation’s role in genome stability, H3K36 methylation in recruitment 
of DNA repair factors through the facilitation of conjoining DNA ends, H3K79 methylation 
recruitment of and localization 53BP1 to DNA break sites, and H3K27/H3K4 methylation which 
block DNA break site transcription and initiate DNA repair1,2,10. Demethylation of modified 
histones is largely carried out by lysine demethylase (LSD1), which removes methyl groups from 
methylated lysines at position 4 of histone 3, regulating gene expression. LSD1 also acts as a 
folate-binding protein, as folate, in the form of THF binds to LSD1 to protect it from damage11. 
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Preliminary studies revealed mice fed folate deficient diets and resulting low folate status in the 
liver was associated with an increase in the methylation of lysine 4, a possible result of decreased 
levels of LSD1. Also, western blotting showed a significant change in H3K4me2, a substrate for 
LSD1, with reduced folate intake, further supporting the positive correlation between folate status 
and LSD1 activity11. Due to the regulatory gene expression role of LSD1, and its utilization of 
THF, a folate co-enzyme, to protect enzymes from damage, folate deficiency is thought to have an 
inhibitory effect on LSD111. This correlation could have far-reaching epigenetic effects, as LSD1 
has been found to demethylate non-histone proteins as well. This can most notably be seen in a 
substrate of LSD1, DNMT1, the enzyme responsible for maintaining DNA methylation during 
replication. LSD1 knockout in mice has been shown to lead to decreased levels of DNMT1, 
resulting in global DNA methylation loss12. If folate deficiency is linked to decreased LSD1 
activity, which is associated with DNA methylation activity, disruption of histone modifications 
can be further implicated in carcinogenesis through their ability to induce irregular gene expression 
and impair DNA damage repair9,12.  
In contrast to genetic changes in cancer, the effects of epigenetic changes are potentially 
reversible, allowing for the utilization of dietary compounds in cancer risk reduction and 
prevention. Given the fact that epigenetics plays a vital role in gene regulation and expression, 
folate has been a focus of this research due to its potential ability of modifying DNA and histone 
methylation, two important factors in cancer development. The combined evidence from animal, 
in vitro, as well as human studies suggests that folate’s effect on these epigenetic changes is largely 
dependent on cell type, cancer severity, target organ, and are gene and site specific3,5,6,15,16,17. While 
animal and in vitro studies have provided significant information about mechanisms of epigenetic 
regulation, it is still unclear about how applicable the research from those studies to human health 
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are, or if some discrepancies exist between in vitro and human studies with regards to human health 
and biology, as methylation status due to folate in rodent livers remains inconclusive6. The few 
human intervention and in vivo studies available have shown consistent significant effects of folate 
status on DNA methylation patterns in cervical, lung, and prostate cancer. While this effect still 
remains dependent on the cell type and specific target gene, this highlights the viability of folate 
in epigenetic changes and cancer risk reduction, as well as the importance for further study into 
folate’s significant cancer targets.  
As the epigenome and its specific pathways remain largely unknown, challenges remain 
for future nutriepigenetic research. Timing and dosing of dietary intervention is critical in the 
efficacy of its epigenetic regulation. Intervention in utero as well as in early life show the most 
promise in cancer risk reduction, but remains largely untested throughout all ages. Although folate 
intake has been positively correlated with genomic DNA methylation and negatively correlated 
with promoter methylation, the length of time needed for sustained epigenetic changes remains 
unknown, as many effects on DNA and histone methylation have shown transient results1,6,12. 
Furthermore, it was shown that folate alone was insignificant in modulating DNA methylation in 
certain cell lines and cancer types, suggesting DNA methylation may circumvent SAM: SAH 
pathways, and greater efficacy may be found when combining different bioactive food compounds 
in human intervention. Further understanding of the role nutrients play on epigenetic changes can 
be used to further develop epigenetic drugs that mimic these effects. A focus on the complete 
mapping of the epigenome can also aid in the development of biomarkers for cancer monitoring 
and risk reduction, as identified histone modifications and DNA methylation changes have already 
begun to be utilized as markers for cancer monitoring10. While the role of folate in DNA 
methylation and histone modification remains controversial, it illustrates the potential ability to 
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reverse epigenetic changes, and through further research of the true impact of nutrition on 
epigenetics, may serve as an important tool in predicting individual cancer risk, as well as 
providing natural therapies for combatting cancer.   
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